Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM313 subcutaneous injection in relapsed/refractory aplastic anemia (Phase Ib/II, China)
CTR20250531Phase 2Active
- Sponsor
- Keymed Biosciences
- Start
- Feb 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of cm313 in aplastic anemia, sponsored by Keymed Biosciences. Started Feb 2025; status: active.
02
Drugs
cm313
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on CTR20250531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250531.